Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 16, 2026
TickeronGET DAILY SIGNALS
Cognex Corporation (CGNX): A Focused Play on Machine Vision and Automation

Cognex Corporation (CGNX): A Focused Play on Machine Vision and Automation

Key Takeaways

  • Cognex Corporation (CGNX) is a leading global provider of machine vision systems, sensors, and barcode readers used to automate manufacturing and distribution.
  • The company was founded in 1981, is headquartered in Natick, Massachusetts, and has been publicly traded on the Nasdaq since 1989.
  • Cognex operates a single business segment focused on machine vision technology and generates revenue primarily from standard products and services across logistics, automotive, consumer electronics, semiconductor, and packaging markets.
  • The company runs a capital-light, high-margin business model with a historically strong balance sheet and no long-term debt.
  • Investors follow CGNX for its exposure to the long-term growth of industrial automation, artificial intelligence (AI), and e-commerce logistics.

Company Background and Operations

Cognex Corporation builds machine vision products that combine hardware and software to let machines “see” and make decisions in factory and warehouse environments. Its systems locate, identify, inspect, and measure items ranging from mobile phones and automotive parts to e-commerce packages. For investors, this offers exposure to the ongoing shift toward industrial automation, where computer vision handles tasks that are too fast, too precise, or too costly for human inspection.

The company was founded in 1981 by Dr. Robert J. Shillman and co-founders William Silver and Marilyn Matz. It is headquartered in Natick, Massachusetts, and has traded publicly on the Nasdaq under the ticker CGNX since 1989. The name “Cognex” is short for “Cognition Experts.” Today it maintains offices and distributors across the Americas, Europe, and Asia, serving more than 30,000 customers worldwide.

Core products include the In-Sight line of vision systems and sensors, the VisionPro software platform, and DataMan image-based barcode readers. Cognex also provides deep-learning and AI-based tools plus cloud offerings that help customers scale vision applications. These support defect detection, assembly verification, robot guidance, and item tracking in logistics. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

From a business perspective, Cognex operates a single reportable segment in machine vision technology. Revenue comes mainly from standard products and services such as vision systems, sensors, barcode readers, software, and accessories, with a smaller portion from application-specific customer solutions. Sales occur through a direct force and distributor network, with close customer involvement across the product lifecycle.

Key markets include logistics, automotive, consumer electronics, packaging, and semiconductors, plus exposure to medical and consumer products. Geographically, revenue spans the United States, Europe, Greater China, and other regions. The financial profile features high gross margins, steady cash generation, and a balance sheet with minimal long-term debt, reflecting an asset-light model.

Why Investors Track CGNX

Investors follow Cognex as a recognized leader in a niche yet structurally growing field. Machine vision sits at the intersection of automation, robotics, and AI, with demand rising as manufacturers and logistics firms invest in efficiency and quality. The company has shipped millions of image-based products since its founding and holds a substantial intellectual property portfolio that supports its position.

Long-term drivers include e-commerce growth that boosts demand for automated scanning and sorting, rising labor costs that encourage automated inspection, and continued investment in AI and deep learning that makes tools more capable and easier to deploy. The direct sales model and long customer relationships provide competitive advantages that support recurring demand.

Risks and Key Considerations

Cognex’s business is cyclical and tied to customer capital spending in manufacturing and logistics. When customers delay or cut factory investments, demand for vision systems can soften, making revenue and earnings sensitive to macroeconomic conditions. Concentration risk exists as well, since a relatively small number of large customers can represent a meaningful share of revenue in any given year.

Competition comes from large automation and sensor firms as well as lower-cost providers and emerging open-source AI tools, which can pressure pricing and margins. Meaningful exposure to Greater China brings risks from trade policies, tariffs, and geopolitical tensions. Reliance on third-party contract manufacturers and some single-source components also leaves the company vulnerable to supply-chain disruptions.

Researching Stocks with AI Tools

When analyzing names like CGNX, I often turn to Tickeron’s AI Screener to quickly compare fundamentals, technical signals, and industry peers. It helps surface ideas that align with a given strategy without replacing deeper fundamental work.

Conclusion

Cognex Corporation stands out as a focused leader in machine vision, a technology central to modern factory and warehouse automation. Its blend of hardware, software, and AI capabilities, combined with a global customer base and strong financial profile, keeps it relevant for investors following the industrial-automation theme. At the same time, cyclical end markets and competitive pressures mean performance can vary with the pace of customer investment. For those seeking to understand the automation and AI-driven manufacturing economy, CGNX remains a notable company to watch.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CGNX

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


CGNX's Indicator enters downward trend

The Aroon Indicator for CGNX entered a downward trend on November 13, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 228 similar instances where the Aroon Indicator formed such a pattern. In 169 of the 228 cases the stock moved lower. This puts the odds of a downward move at 74%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CGNX as a result. In 61 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 67%.

The Moving Average Convergence Divergence Histogram (MACD) for CGNX turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 32 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 73%.

CGNX moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for CGNX crossed bearishly below the 50-day moving average on October 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 69%.

The 50-day moving average for CGNX moved below the 200-day moving average on November 12, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CGNX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CGNX's RSI Indicator exited the oversold zone, 16 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 50%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 38 of 53 cases where CGNX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 72%.

Following a +2.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where CGNX advanced for three days, in 175 of 278 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.

CGNX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. CGNX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 66 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.932) is normal, around the industry mean (1.448). P/E Ratio (45.505) is within average values for comparable stocks, (5.350). Projected Growth (PEG Ratio) (0.450) is also within normal values, averaging (5.470). Dividend Yield (0.007) settles around the average of (0.012) among similar stocks. P/S Ratio (9.337) is also within normal values, averaging (32.028).

The Tickeron PE Growth Rating for this company is 73 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CGNX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.

Industry description

This industry manufactures electronic products used in various critical and sophisticated technologies, including laser-based systems, circuit and continuity testers, electro-optical measuring instruments and high-speed precision weighing and inspection equipment. Some major companies operating in this business are Canon Inc., Keysight Technologies Inc., and Fortive Corp.

Market Cap

The average market capitalization across the Electronic Equipment/Instruments Industry is 7.99B. The market cap for tickers in the group ranges from 12.56K to 120.89B. KYCCF holds the highest valuation in this group at 120.89B. The lowest valued company is FLXT at 12.56K.

High and low price notable news

The average weekly price growth across all stocks in the Electronic Equipment/Instruments Industry was 5%. For the same Industry, the average monthly price growth was -5%, and the average quarterly price growth was -13%. FCUV experienced the highest price growth at 130%, while ARAI experienced the biggest fall at -51%.

Volume

The average weekly volume growth across all stocks in the Electronic Equipment/Instruments Industry was 87%. For the same stocks of the Industry, the average monthly volume growth was 232% and the average quarterly volume growth was 107%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 57
P/E Growth Rating: 50
Price Growth Rating: 61
SMR Rating: 78
Profit Risk Rating: 81
Seasonality Score: 6 (-100 ... +100)
AI Patterns 1
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of machine vision computer systems

Industry ElectronicEquipmentInstruments

Industry
Electronic Production Equipment
Address
One Vision Drive
Phone
+1 508 650-3000
Employees
2745
Web
https://www.cognex.com
Interact to see
Advertisement
The central price target used here is $400 , roughly 35% above Alphabet's latest verified closing price of $295.77 (November 13, 2026). This target is the arithmetic mean of verified analyst price targets reviewed, not a single analyst's forecast; independent data providers report comparable consensus averages in the high-$390s to low-$400s.
Upcoming catalysts: Integration of advertising into AI Overviews and Gemini conversations, the scaling of Gemini 3 and newer models across Search and Cloud, and the commercial ramp of the $32 billion Wiz cloud-security acquisition could all shape sentiment into 2026. Strategic positioning: Alphabet's vertically integrated artificial intelligence (AI) stack — from custom TPU (Tensor Processing Unit) chips to the Gemini models to Google Cloud — supports a durable, cost-advantaged position in the AI build-out.
The TETH exchange-traded fund (ETF) is the 21Shares Ethereum Staking ETF, a spot Ethereum fund listed on Cboe BZX, and it does not carry conventional analyst price targets. The $14 objective used here is a technical milestone discussed in public market commentary — roughly the zone where Ethereum could begin confirming a recovery — not an analyst consensus.
The central target of $6.70 is the arithmetic mean of seven recent, individually verified analyst price targets, rounded from $6.67. At a latest price near $3.70, reaching $6.70 would require roughly 81% upside — a very large move.
Lead catalyst: Chemomab has secured alignment with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) on a single Phase 3 registration trial for nebokitug in primary sclerosing cholangitis (PSC), a rare liver disease with no approved disease-modifying therapy. Strategic pivot: A planned merger with Scipher Medicine is expected to close by year-end 2026, extending nebokitug into an AI-powered, precision-medicine Phase 2 trial in rheumatoid arthritis (RA).